, /PRNewswire/ -- presented new TARGET- real-world data studies that analyzed glucagon-like peptide 1 (GLP-1) use and the -CHECK patient-reported outcome (PRO) measures at the 2024 European Association for the Study of the Liver (EASL), in . The presentations included " " and " As GLP-1 receptor agonists are approved in the U.S.
for diabetes and obesity, there is considerable interest in using this class of medications in patients with metabolic dysfunction associated with steatotic liver disease (MASLD); however, little observational data exists for this population. In the new analysis leveraging data from the U.S.
TARGET- observational cohort, researchers described that 11% of the adult cohort, including patients with MASL, metabolic dysfunction-associated steatohepatitis (MASH), and MASLD with cirrhosis were prescribed GLP-1 therapy. "GLP-1 treatments are at the forefront of metabolic liver research driven by the high prevalence of type 2 diabetes and obesity. Given that obesity and cardiovascular disease also continue to represent high rates of comorbidities in the MASLD population, it's imperative to patient characteristics among those who have been prescribed a GLP-1 in a real-world setting to better inform potential treatment pathways.
Real-world evidence can be our roadmap to turning the tide on serious metabolic liver diseases." A. , MD, MSCR, Professor of Medicine, Director of Hepatology, and Transplant Hepatology Program Director in the Division of Gastroenterology.
